AstraZeneca to Buy Takeda Respiratory Biz

Source: Bloomberg

Dec 17, 2015

London-based AstraZeneca has agreed to buy a respiratory business from Japan’s Takeda Pharmaceutical for $575 million to gain global rights to the lung treatment roflumilast.

AstraZeneca currently markets roflumilast in the U.S. under the brand name Daliresp. The new deal will help AstraZeneca grow its Japan operations, as well as give the drugmaker access to promising pipeline products.

Simultaneously, AstraZeneca also announced an alliance with China’s WuXi AppTec, a research and development platform, to investigate biological medicines.

Read the Bloomberg press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments